Dr. Greeshma Shetty

Yeah. So when folks increase their fat intake and certainly when people achieve nutritional ketosis with higher ketone levels, the hormones that drive appetite are naturally suppressed and the hormones that signal satiety go up. So endogenous GLP-1, CCK go up and then things like ghrelin go down.

So again, so exactly like harnessing nutrition to appropriately do that positive feed loop that's towards improving health and decreasing hunger. It drives with just the nutritional changes.

So again, so exactly like harnessing nutrition to appropriately do that positive feed loop that's towards improving health and decreasing hunger. It drives with just the nutritional changes.

So again, so exactly like harnessing nutrition to appropriately do that positive feed loop that's towards improving health and decreasing hunger. It drives with just the nutritional changes.

Yeah, no, I think that's a great question. And it kind of hits on something we spoke about earlier during this call with insulin and how we sort of, I think we missed an opportunity of marrying some of the nutritional sciences to patients who were able to receive insulin. And when you think of like Even type 1 diabetes, of course, insulin was life-saving.

Yeah, no, I think that's a great question. And it kind of hits on something we spoke about earlier during this call with insulin and how we sort of, I think we missed an opportunity of marrying some of the nutritional sciences to patients who were able to receive insulin. And when you think of like Even type 1 diabetes, of course, insulin was life-saving.

Yeah, no, I think that's a great question. And it kind of hits on something we spoke about earlier during this call with insulin and how we sort of, I think we missed an opportunity of marrying some of the nutritional sciences to patients who were able to receive insulin. And when you think of like Even type 1 diabetes, of course, insulin was life-saving.

But because we didn't really invest in figuring out the right nutritional, now we have a lot of folks with type 1 diabetes who we say they have double diabetes, which is type 1 with insulin resistance. Because we've just let people eat whatever they want, even if it doesn't work for their body. So I like to think of that as an analogy for GLP-1s.

But because we didn't really invest in figuring out the right nutritional, now we have a lot of folks with type 1 diabetes who we say they have double diabetes, which is type 1 with insulin resistance. Because we've just let people eat whatever they want, even if it doesn't work for their body. So I like to think of that as an analogy for GLP-1s.

But because we didn't really invest in figuring out the right nutritional, now we have a lot of folks with type 1 diabetes who we say they have double diabetes, which is type 1 with insulin resistance. Because we've just let people eat whatever they want, even if it doesn't work for their body. So I like to think of that as an analogy for GLP-1s.

You just can't eat whatever you want just because there's a new medication. Because guess what? Again, the energy homeostasis is super complex. There's no silver bullet. Like you actually have to eat right for your body. And there's so many, like I said, the genome wide studies have shown that there's a lot of different types of type 2 diabetes.

You just can't eat whatever you want just because there's a new medication. Because guess what? Again, the energy homeostasis is super complex. There's no silver bullet. Like you actually have to eat right for your body. And there's so many, like I said, the genome wide studies have shown that there's a lot of different types of type 2 diabetes.

You just can't eat whatever you want just because there's a new medication. Because guess what? Again, the energy homeostasis is super complex. There's no silver bullet. Like you actually have to eat right for your body. And there's so many, like I said, the genome wide studies have shown that there's a lot of different types of type 2 diabetes.

And if we can get to the root cause, we can help a lot of folks and not look at one target molecule that we're using today, which is the GLP-1 therapy and that. So I think really thinking more holistically about our patients that these are not magic bullets.

And if we can get to the root cause, we can help a lot of folks and not look at one target molecule that we're using today, which is the GLP-1 therapy and that. So I think really thinking more holistically about our patients that these are not magic bullets.

And if we can get to the root cause, we can help a lot of folks and not look at one target molecule that we're using today, which is the GLP-1 therapy and that. So I think really thinking more holistically about our patients that these are not magic bullets.

Look, they're great medications for patients with diabetes and other non-glycemic indications like reasons outside of blood sugar control, such as heart disease, heart failure, kidney disease. There's mortality and there's outcomes data to support their use. But what about like,

Look, they're great medications for patients with diabetes and other non-glycemic indications like reasons outside of blood sugar control, such as heart disease, heart failure, kidney disease. There's mortality and there's outcomes data to support their use. But what about like,

Look, they're great medications for patients with diabetes and other non-glycemic indications like reasons outside of blood sugar control, such as heart disease, heart failure, kidney disease. There's mortality and there's outcomes data to support their use. But what about like,

the millions of people who have not yet developed those complications who have diabetes and the folks who have prediabetes and obesity. And this is, you know, diabetes is the tip of the iceberg, right? We have a whole society below that where we need to drive impact because we can't just medicate everybody in the country.